Cellosaurus logo
expasy logo

Cellosaurus TCC-SUPrGEMCI20 (CVCL_RR25)

[Text version]
Cell line name TCC-SUPrGEMCI20
Accession CVCL_RR25
Resource Identification Initiative To cite this cell line use: TCC-SUPrGEMCI20 (RRID:CVCL_RR25)
Comments Part of: Resistant Cancer Cell Line (RCCL) collection.
Population: Caucasian.
Doubling time: 117.8 hours (PubMed=26055179).
Selected for resistance to: ChEBI; CHEBI_175901; Gemcitabine (Gemzar).
Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
Sequence variations
  • Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
  • Mutation; HGNC; HGNC:11998; TP53; Simple; p.Glu349Ter (c.1045G>T); ClinVar=VCV000634695; Zygosity=Homozygous (from parent cell line).
Disease Bladder carcinoma (NCIt: C4912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1738 (TCCSUP)
Sex of cell Female
Age at sampling 67Y
Category Cancer cell line
Web pages https://www.wass-michaelislab.org/rccl.php
Publications

PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002; PMCID=PMC4487788
Vallo S., Michaelis M., Rothweiler F., Bartsch G., Gust K.M., Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.
Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics.
Transl. Oncol. 8:210-216(2015)

Cross-references
Cell line databases/resources cancercelllines; CVCL_RR25
Encyclopedic resources Wikidata; Q54971865
Entry history
Entry creation05-Mar-2018
Last entry update19-Dec-2024
Version number12